Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 59

1.

Modulation of Circulating Protein Biomarkers in Cancer Patients Receiving Bevacizumab and the Anti-Endoglin Antibody TRC105.

Liu Y, Starr MD, Brady JC, Rushing C, Pang H, Adams B, Alvarez D, Theuer CP, Hurwitz HI, Nixon AB.

Mol Cancer Ther. 2018 Jul 11. pii: molcanther.0916.2017. doi: 10.1158/1535-7163.MCT-17-0916. [Epub ahead of print]

PMID:
29997150
2.

Cabozantinib in ovarian clear cell cancers: UnMET expectations.

Secord AA, Previs RA, Nixon AB.

Gynecol Oncol. 2018 Jul;150(1):1-2. doi: 10.1016/j.ygyno.2018.06.006. No abstract available.

PMID:
29935857
3.

Bevacizumab biosimilars: scientific justification for extrapolation of indications.

Melosky B, Reardon DA, Nixon AB, Subramanian J, Bair AH, Jacobs I.

Future Oncol. 2018 Apr 25. doi: 10.2217/fon-2018-0051. [Epub ahead of print]

4.

A Phase I Trial of the IGF-1R Antibody Ganitumab (AMG 479) in Combination with Everolimus (RAD001) and Panitumumab in Patients with Advanced Cancer.

Vlahovic G, Meadows KL, Hatch AJ, Jia J, Nixon AB, Uronis HE, Morse MA, Selim MA, Crawford J, Riedel RF, Zafar SY, Howard LA, O'Neill M, Meadows JJ, Haley ST, Arrowood CC, Rushing C, Pang H, Hurwitz HI.

Oncologist. 2018 Mar 23. pii: theoncologist.2016-0377. doi: 10.1634/theoncologist.2016-0377. [Epub ahead of print]

PMID:
29572245
5.

Association of Tumor HER3 Messenger RNA Expression With Panitumumab Efficacy in Advanced Colorectal Cancer.

Seligmann JF, Hatch AJ, Richman SD, Elliott F, Jacobs B, Brown S, Hurwitz H, Barrett JH, Quirke P, Nixon AB, Seymour MT.

JAMA Oncol. 2018 Apr 1;4(4):564-568. doi: 10.1001/jamaoncol.2017.3168.

PMID:
29075780
6.

Pilot Evaluation of Angiogenesis Signaling Factor Response after Transcatheter Arterial Embolization for Hepatocellular Carcinoma.

Ronald J, Nixon AB, Marin D, Gupta RT, Janas G, Chen W, Suhocki PV, Pabon-Ramos W, Sopko DR, Starr MD, Brady JC, Hurwitz HI, Kim CY.

Radiology. 2017 Oct;285(1):311-318. doi: 10.1148/radiol.2017162555. Epub 2017 Aug 8.

PMID:
28787261
7.

The role of angiogenesis in Group 3 medulloblastoma pathogenesis and survival.

Thompson EM, Keir ST, Venkatraman T, Lascola C, Yeom KW, Nixon AB, Liu Y, Picard D, Remke M, Bigner DD, Ramaswamy V, Taylor MD.

Neuro Oncol. 2017 Sep 1;19(9):1217-1227. doi: 10.1093/neuonc/nox033.

PMID:
28379574
8.

TGF-β-induced stromal CYR61 promotes resistance to gemcitabine in pancreatic ductal adenocarcinoma through downregulation of the nucleoside transporters hENT1 and hCNT3.

Hesler RA, Huang JJ, Starr MD, Treboschi VM, Bernanke AG, Nixon AB, McCall SJ, White RR, Blobe GC.

Carcinogenesis. 2016 Nov 1;37(11):1041-1051. doi: 10.1093/carcin/bgw093.

9.

Metastatic clear cell renal cell carcinoma: Circulating biomarkers to guide antiangiogenic and immune therapies.

Zhang T, Zhu J, George DJ, Nixon AB.

Urol Oncol. 2016 Nov;34(11):510-518. doi: 10.1016/j.urolonc.2016.06.020. Epub 2016 Aug 4. Review.

PMID:
27498927
10.

Blood-based markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance).

Hatch AJ, Sibley AB, Starr MD, Brady JC, Jiang C, Jia J, Bowers DL, Pang H, Owzar K, Niedzwiecki D, Innocenti F, Venook AP, Hurwitz HI, Nixon AB; Alliance for Clinical Trials in Oncology.

Cancer Med. 2016 Sep;5(9):2249-60. doi: 10.1002/cam4.806. Epub 2016 Jul 27.

11.

A Molecular Model for Predicting Overall Survival in Patients with Metastatic Clear Cell Renal Carcinoma: Results from CALGB 90206 (Alliance).

Kim HL, Halabi S, Li P, Mayhew G, Simko J, Nixon AB, Small EJ, Rini B, Morris MJ, Taplin ME, George D; Alliance for Clinical Trials in Oncology.

EBioMedicine. 2015 Sep 8;2(11):1814-20. doi: 10.1016/j.ebiom.2015.09.012. eCollection 2015 Nov.

12.

Identifying Blood-Based Protein Biomarkers for Antiangiogenic Agents in the Clinic: A Decade of Progress.

Hatch AJ, Clarke JM, Nixon AB, Hurwitz HI.

Cancer J. 2015 Jul-Aug;21(4):322-6. doi: 10.1097/PPO.0000000000000129. Review.

PMID:
26222085
13.

Direct Evidence of Target Inhibition with Anti-VEGF, EGFR, and mTOR Therapies in a Clinical Model of Wound Healing.

Jia J, Dellinger AE, Weiss ES, Bulusu A, Rushing C, Li H, Howard LA, Kaplan N, Pang H, Hurwitz HI, Nixon AB.

Clin Cancer Res. 2015 Aug 1;21(15):3442-52. doi: 10.1158/1078-0432.CCR-14-2819. Epub 2015 Apr 15.

14.

Biomarker signatures correlate with clinical outcome in refractory metastatic colorectal cancer patients receiving bevacizumab and everolimus.

Liu Y, Starr MD, Brady JC, Rushing C, Bulusu A, Pang H, Honeycutt W, Amara A, Altomare I, Uronis HE, Hurwitz HI, Nixon AB.

Mol Cancer Ther. 2015 Apr;14(4):1048-56. doi: 10.1158/1535-7163.MCT-14-0923-T. Epub 2015 Feb 18.

15.

A leave-one-out cross-validation SAS macro for the identification of markers associated with survival.

Rushing C, Bulusu A, Hurwitz HI, Nixon AB, Pang H.

Comput Biol Med. 2015 Feb;57:123-9. doi: 10.1016/j.compbiomed.2014.11.015. Epub 2014 Dec 9.

16.

A Phase I/biomarker study of bevacizumab in combination with CNTO 95 in patients with advanced solid tumors.

Uronis HE, Jia J, Bendell JC, Howard L, Ready NA, Lee PH, Starr MD, Dellinger A, Pang H, Nixon AB, Hurwitz HI.

Cancer Chemother Pharmacol. 2015 Feb;75(2):343-52. doi: 10.1007/s00280-014-2647-x. Epub 2014 Dec 20.

PMID:
25527204
17.

Gene expression markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance).

Cushman SM, Jiang C, Hatch AJ, Shterev I, Sibley AB, Niedzwiecki D, Venook AP, Owzar K, Hurwitz HI, Nixon AB.

Clin Cancer Res. 2015 Mar 1;21(5):1078-86. doi: 10.1158/1078-0432.CCR-14-2313. Epub 2014 Dec 17.

18.

The search for biomarkers to direct antiangiogenic treatment in epithelial ovarian cancer.

Secord AA, Nixon AB, Hurwitz HI.

Gynecol Oncol. 2014 Nov;135(2):349-58. doi: 10.1016/j.ygyno.2014.08.033. Epub 2014 Aug 30. Review.

PMID:
25178997
19.

Integrative Pathway Analysis Using Graph-Based Learning with Applications to TCGA Colon and Ovarian Data.

Dellinger AE, Nixon AB, Pang H.

Cancer Inform. 2014 Jul 28;13(Suppl 4):1-9. doi: 10.4137/CIN.S13634. eCollection 2014.

20.

The balance of cell surface and soluble type III TGF-β receptor regulates BMP signaling in normal and cancerous mammary epithelial cells.

Gatza CE, Elderbroom JL, Oh SY, Starr MD, Nixon AB, Blobe GC.

Neoplasia. 2014 Jun;16(6):489-500. doi: 10.1016/j.neo.2014.05.008.

21.

Effects of the combination of TRC105 and bevacizumab on endothelial cell biology.

Liu Y, Tian H, Blobe GC, Theuer CP, Hurwitz HI, Nixon AB.

Invest New Drugs. 2014 Oct;32(5):851-9. doi: 10.1007/s10637-014-0129-y. Epub 2014 Jul 5.

22.

Ectodomain shedding of TβRIII is required for TβRIII-mediated suppression of TGF-β signaling and breast cancer migration and invasion.

Elderbroom JL, Huang JJ, Gatza CE, Chen J, How T, Starr M, Nixon AB, Blobe GC.

Mol Biol Cell. 2014 Aug 15;25(16):2320-32. doi: 10.1091/mbc.E13-09-0524. Epub 2014 Jun 25.

23.

Stromal heparan sulfate differentiates neuroblasts to suppress neuroblastoma growth.

Knelson EH, Gaviglio AL, Nee JC, Starr MD, Nixon AB, Marcus SG, Blobe GC.

J Clin Invest. 2014 Jul;124(7):3016-31. doi: 10.1172/JCI74270. Epub 2014 Jun 17.

24.

Role of TGF-β receptor III localization in polarity and breast cancer progression.

Meyer AE, Gatza CE, How T, Starr M, Nixon AB, Blobe GC.

Mol Biol Cell. 2014 Aug 1;25(15):2291-304. doi: 10.1091/mbc.E14-03-0825. Epub 2014 May 28.

25.

Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors.

Rangwala F, Bendell JC, Kozloff MF, Arrowood CC, Dellinger A, Meadows J, Tourt-Uhlig S, Murphy J, Meadows KL, Starr A, Broderick S, Brady JC, Cushman SM, Morse MA, Uronis HE, Hsu SD, Zafar SY, Wallace J, Starodub AN, Strickler JH, Pang H, Nixon AB, Hurwitz HI.

Invest New Drugs. 2014 Aug;32(4):700-9. doi: 10.1007/s10637-014-0089-2. Epub 2014 Apr 9.

26.

A phase Ib study of combined VEGFR and mTOR inhibition with vatalanib and everolimus in patients with advanced renal cell carcinoma.

Bitting RL, Healy P, Creel PA, Turnbull J, Morris K, Wood SY, Hurwitz HI, Starr MD, Nixon AB, Armstrong AJ, George DJ.

Clin Genitourin Cancer. 2014 Aug;12(4):241-50. doi: 10.1016/j.clgc.2013.11.020. Epub 2013 Nov 14.

27.

Modulation of circulating protein biomarkers following TRC105 (anti-endoglin antibody) treatment in patients with advanced cancer.

Liu Y, Starr MD, Brady JC, Dellinger A, Pang H, Adams B, Theuer CP, Lee NY, Hurwitz HI, Nixon AB.

Cancer Med. 2014 Jun;3(3):580-91. doi: 10.1002/cam4.207. Epub 2014 Feb 14.

28.

Dasatinib (BMS-35482) interacts synergistically with docetaxel, gemcitabine, topotecan, and doxorubicin in ovarian cancer cells with high SRC pathway activation and protein expression.

Secord AA, Teoh D, Jia J, Nixon AB, Grace L, Adams DJ, Murphy SK.

Int J Gynecol Cancer. 2014 Feb;24(2):218-25. doi: 10.1097/IGC.0000000000000056.

29.

Dasatinib (BMS-35482) potentiates the activity of gemcitabine and docetaxel in uterine leiomyosarcoma cell lines.

Lopez-Acevedo M, Grace L, Teoh D, Whitaker R, Adams DJ, Jia J, Nixon AB, Secord AA.

Gynecol Oncol Res Pract. 2014 Sep 30;1:2. doi: 10.1186/2053-6844-1-2. eCollection 2014.

30.

Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer.

Strickler JH, McCall S, Nixon AB, Brady JC, Pang H, Rushing C, Cohn A, Starodub A, Arrowood C, Haley S, Meadows KL, Morse MA, Uronis HE, Blobe GC, Hsu SD, Zafar SY, Hurwitz HI.

Invest New Drugs. 2014 Apr;32(2):330-9. doi: 10.1007/s10637-013-0042-9. Epub 2013 Nov 1.

31.

Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: results from CALGB80303 (Alliance).

Nixon AB, Pang H, Starr MD, Friedman PN, Bertagnolli MM, Kindler HL, Goldberg RM, Venook AP, Hurwitz HI; Alliance for Clinical Trials In Oncology.

Clin Cancer Res. 2013 Dec 15;19(24):6957-66. doi: 10.1158/1078-0432.CCR-13-0926. Epub 2013 Oct 4.

32.

Antibody-directed coupling of endoglin and MMP-14 is a key mechanism for endoglin shedding and deregulation of TGF-β signaling.

Kumar S, Pan CC, Bloodworth JC, Nixon AB, Theuer C, Hoyt DG, Lee NY.

Oncogene. 2014 Jul 24;33(30):3970-9. doi: 10.1038/onc.2013.386. Epub 2013 Sep 30.

33.

A phase I study of ABT-510 plus bevacizumab in advanced solid tumors.

Uronis HE, Cushman SM, Bendell JC, Blobe GC, Morse MA, Nixon AB, Dellinger A, Starr MD, Li H, Meadows K, Gockerman J, Pang H, Hurwitz HI.

Cancer Med. 2013 Jun;2(3):316-24. doi: 10.1002/cam4.65. Epub 2013 Mar 21.

34.

Correlation of angiogenic biomarker signatures with clinical outcomes in metastatic colorectal cancer patients receiving capecitabine, oxaliplatin, and bevacizumab.

Liu Y, Starr MD, Bulusu A, Pang H, Wong NS, Honeycutt W, Amara A, Hurwitz HI, Nixon AB.

Cancer Med. 2013 Apr;2(2):234-42. doi: 10.1002/cam4.71. Epub 2013 Mar 6.

35.

A phase II study of capecitabine, oxaliplatin, and bevacizumab in the treatment of metastatic esophagogastric adenocarcinomas.

Uronis HE, Bendell JC, Altomare I, Blobe GC, Hsu SD, Morse MA, Pang H, Zafar SY, Conkling P, Favaro J, Arrowood CC, Cushman SM, Meadows KL, Brady JC, Nixon AB, Hurwitz HI.

Oncologist. 2013;18(3):271-2. doi: 10.1634/theoncologist.2012-0404. Epub 2013 Mar 13.

36.

Dual inhibition of αV integrins and Src kinase activity as a combination therapy strategy for colorectal cancer.

Jia J, Starodub A, Cushman I, Liu Y, Marshall DJ, Hurwitz HI, Nixon AB.

Anticancer Drugs. 2013 Mar;24(3):237-50. doi: 10.1097/CAD.0b013e32835d29fd.

37.

Phase I study of bevacizumab, everolimus, and panobinostat (LBH-589) in advanced solid tumors.

Strickler JH, Starodub AN, Jia J, Meadows KL, Nixon AB, Dellinger A, Morse MA, Uronis HE, Marcom PK, Zafar SY, Haley ST, Hurwitz HI.

Cancer Chemother Pharmacol. 2012 Aug;70(2):251-8. doi: 10.1007/s00280-012-1911-1. Epub 2012 Jun 29.

38.

A phase II study of capecitabine, oxaliplatin, bevacizumab and cetuximab in the treatment of metastatic colorectal cancer.

Wong NS, Fernando NH, Nixon AB, Cushman S, Aklilu M, Bendell JC, Morse MA, Blobe GC, Ashton J, Pang H, Hurwitz HI.

Anticancer Res. 2011 Jan;31(1):255-61.

39.

A phase I dose-escalation study of imatinib mesylate (Gleevec/STI571) plus capecitabine (Xeloda) in advanced solid tumors.

Dugan E, Truax R, Meadows KL, Nixon AB, Petros WP, Favaro J, Fernando NH, Morse MA, Blobe GC, Hurwitz HI.

Anticancer Res. 2010 Apr;30(4):1251-6.

40.

Effect of pazopanib on tumor microenvironment and liposome delivery.

Tailor TD, Hanna G, Yarmolenko PS, Dreher MR, Betof AS, Nixon AB, Spasojevic I, Dewhirst MW.

Mol Cancer Ther. 2010 Jun;9(6):1798-808. doi: 10.1158/1535-7163.MCT-09-0856. Epub 2010 Jun 1.

41.

Vascular endothelial growth factor receptor 2 controls blood pressure by regulating nitric oxide synthase expression.

Facemire CS, Nixon AB, Griffiths R, Hurwitz H, Coffman TM.

Hypertension. 2009 Sep;54(3):652-8. doi: 10.1161/HYPERTENSIONAHA.109.129973. Epub 2009 Aug 3.

42.

The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients.

Osada T, Chong G, Tansik R, Hong T, Spector N, Kumar R, Hurwitz HI, Dev I, Nixon AB, Lyerly HK, Clay T, Morse MA.

Cancer Immunol Immunother. 2008 Aug;57(8):1115-24. doi: 10.1007/s00262-007-0441-x. Epub 2008 Jan 10.

43.

A role for G(z) in pancreatic islet beta-cell biology.

Kimple ME, Nixon AB, Kelly P, Bailey CL, Young KH, Fields TA, Casey PJ.

J Biol Chem. 2005 Sep 9;280(36):31708-13. Epub 2005 Jul 6.

44.
45.

Regulation of platelet-activating factor synthesis in human neutrophils by MAP kinases.

Baker PR, Owen JS, Nixon AB, Thomas L, Wooten R, Daniel LW, O'Flaherty JT, Wykle RL.

Biochim Biophys Acta. 2002 Oct 21;1592(2):175-84.

46.

The interaction of RGSZ1 with SCG10 attenuates the ability of SCG10 to promote microtubule disassembly.

Nixon AB, Grenningloh G, Casey PJ.

J Biol Chem. 2002 May 17;277(20):18127-33. Epub 2002 Mar 6.

47.

Phosphorylation and nuclear translocation of a regulator of G protein signaling (RGS10).

Burgon PG, Lee WL, Nixon AB, Peralta EG, Casey PJ.

J Biol Chem. 2001 Aug 31;276(35):32828-34. Epub 2001 Jul 6.

48.

Acetyl-CoA:1-O-alkyl-2-lyso-sn-glycero-3-phosphocholine acetyltransferase is directly activated by p38 kinase.

Nixon AB, O'Flaherty JT, Salyer JK, Wykle RL.

J Biol Chem. 1999 Feb 26;274(9):5469-73.

49.
50.

Comparison of alkylacylglycerol vs. diacylglycerol as activators of mitogen-activated protein kinase and cytosolic phospholipase A2 in human neutrophil priming.

Nixon AB, Seeds MC, Bass DA, Smitherman PK, O'Flaherty JT, Daniel LW, Wykle RL.

Biochim Biophys Acta. 1997 Aug 16;1347(2-3):219-30.

PMID:
9295167

Supplemental Content

Loading ...
Support Center